MARKET

EYEG

EYEG

EyeGate Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.57
-0.08
-1.42%
Closed 16:00 03/02 EST
OPEN
5.73
PREV CLOSE
5.65
HIGH
5.80
LOW
5.50
VOLUME
36.95K
TURNOVER
--
52 WEEK HIGH
8.18
52 WEEK LOW
3.200
MARKET CAP
25.77M
P/E (TTM)
-2.8333
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Analysts Offer Insights on Healthcare Companies: Eyegate (EYEG), Tiziana Life Sciences (TLSA) and Mustang Bio (MBIO)
SmarterAnalyst · 02/03 11:25
EyeGate Pharmaceuticals Announces Management Transition In Support of Strategic Transformation
GlobeNewswire · 02/01 11:55
EyeGate Pharmaceuticals Announces Management Transition In Support of Strategic Transformation
GlobeNewswire · 02/01 11:55
*DJ Eyegate Pharmaceuticals: Stephen From Elevated From CEO to Executive Chmn >EYEG
Dow Jones · 02/01 11:55
*DJ Eyegate Pharmaceuticals Names Franz Obermayr Acting CEO, Transitioning From EVP Clinical Development >EYEG
Dow Jones · 02/01 11:55
Press Release: EyeGate Pharmaceuticals Announces Management Transition In Support of Strategic Transformation
Dow Jones · 02/01 11:55
EyeGate Pharmaceuticals Announces Management Transition In Support of Strategic Transformation
- Franz Obermayr, Ph.D. Appointed as Acting Chief Executive Officer, Transitioning From EVP Clinical Development - - Stephen From Elevated from Chief Executive Officer to Executive Chairman - WALTHAM, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharma...
GlobeNewswire · 02/01 11:55
LLY, GME, NIO and BNGO among notable premarket gainers
Mesoblaston (MESO) +68% after announcing additional results from the DREAM-HF Phase 3 trial.TransEnterix (TRXC) +64%.LM Funding America (LMFA) +49%.Aileron Therapeutics (ALRN) +35%.Bionano Genomics (BNGO) +24% after announcing first publication from the COVID-19
Seekingalpha · 01/11 13:28
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EYEG. Analyze the recent business situations of EyeGate Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EYEG stock price target is 15.25 with a high estimate of 16.75 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 30
Institutional Holdings: 1.92M
% Owned: 41.46%
Shares Outstanding: 4.63M
TypeInstitutionsShares
Increased
2
15.19K
New
4
-341
Decreased
2
23.34K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.38%
Pharmaceuticals & Medical Research
-0.88%
Key Executives
Chairman/Executive Director
Stephen From
Chief Executive Officer
Franz Obermayr
Chief Financial Officer
Sarah Romano
Vice President
Michael Manzo
Lead Director/Independent Director
Paul Chaney
Director
Steven Boyd
Director
I. Keith Maher
Other
Mike Garanzini
Director
Keith Maher
Independent Director
Morton Goldberg
Independent Director
Thomas Hancock
Independent Director
Bernard Malfroy-Camine
Independent Director
Praveen Tyle
  • Dividends
  • Splits
  • Insider Activity
No Data
About EYEG
Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.

Webull offers kinds of Eyegate Pharmaceuticals Inc stock information, including NASDAQ:EYEG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EYEG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EYEG stock methods without spending real money on the virtual paper trading platform.